MX2011011186A - Una vacuna antituberculosis tb para evitar la reactivacion. - Google Patents

Una vacuna antituberculosis tb para evitar la reactivacion.

Info

Publication number
MX2011011186A
MX2011011186A MX2011011186A MX2011011186A MX2011011186A MX 2011011186 A MX2011011186 A MX 2011011186A MX 2011011186 A MX2011011186 A MX 2011011186A MX 2011011186 A MX2011011186 A MX 2011011186A MX 2011011186 A MX2011011186 A MX 2011011186A
Authority
MX
Mexico
Prior art keywords
tuberculosis
vaccine
prevent reactivation
infection
reactivation
Prior art date
Application number
MX2011011186A
Other languages
English (en)
Inventor
Jes Dietrich
Peter Andersen
Carina Vingsbo Lundberg
Truc Thi Kim Than Hoang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MX2011011186A publication Critical patent/MX2011011186A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

La presente invención describe una vacuna o composición inmunogénica que puede administrarse a individuos infectados de manera latente para evitar la reactivación de la infección latente de tuberculosis causada por especies de los microorganismos del complejo tuberculosis (Mycobacterium tuberculosis, M. bovis y M. africanum), la inverición se basa en un número de proteínas derivadas de M. tuberculosis y fragmentos proteínicos que se expresan constitutivamente en diferentes etapas de la infección. La invención se dirige al uso de estos polipéptidos, sus fragmentos inmunológicamente activos y a los genes que los codifican para composiciones inmunológicas tales como vacunas.
MX2011011186A 2009-04-24 2010-04-23 Una vacuna antituberculosis tb para evitar la reactivacion. MX2011011186A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24
PCT/DK2010/000054 WO2010121618A1 (en) 2009-04-24 2010-04-23 A tuberculosis tb vaccine to prevent reactivation

Publications (1)

Publication Number Publication Date
MX2011011186A true MX2011011186A (es) 2012-02-13

Family

ID=43010694

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009347A MX370744B (es) 2009-04-24 2010-04-23 Una vacuna antituberculosis tb para evitar la reactivación.
MX2011011186A MX2011011186A (es) 2009-04-24 2010-04-23 Una vacuna antituberculosis tb para evitar la reactivacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015009347A MX370744B (es) 2009-04-24 2010-04-23 Una vacuna antituberculosis tb para evitar la reactivación.

Country Status (17)

Country Link
US (2) US9074001B2 (es)
EP (1) EP2421557B1 (es)
JP (2) JP5839361B2 (es)
KR (2) KR20120014176A (es)
CN (2) CN102413837B (es)
AU (1) AU2010238943B9 (es)
BR (1) BRPI1006452A2 (es)
CA (1) CA2759583C (es)
DK (1) DK2421557T3 (es)
ES (1) ES2714383T3 (es)
HK (2) HK1204549A1 (es)
IL (1) IL215591A (es)
MX (2) MX370744B (es)
PL (1) PL2421557T3 (es)
TR (1) TR201903223T4 (es)
WO (1) WO2010121618A1 (es)
ZA (1) ZA201108564B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
PL2315597T3 (pl) 2008-07-25 2018-01-31 Glaxosmithkline Biologicals Sa Nowe kompozycje i sposoby
LT2315773T (lt) * 2008-07-25 2016-11-10 Glaxosmithkline Biologicals S.A. Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui
MX2011000982A (es) 2008-07-25 2011-03-02 Glaxosmithkline Biolog Sa La proteina de tuberculosis rv2386c, composiciones y usos de la misma.
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
HUE032409T2 (en) 2011-01-04 2017-09-28 Archivel Farma Sl Liposome preparation for treating or preventing tuberculosis
PT2802345T (pt) 2012-01-12 2018-04-24 Archivel Farma Sl Vacina mtb-c contra a asma
WO2014063704A2 (en) * 2012-10-23 2014-05-01 Statens Serum Institut M. tuberculosis vaccines
EP2968496A4 (en) * 2013-03-15 2016-07-27 Univ Pennsylvania SYNTHESIS IMMUNOGENS FOR PROPHYLAXIS OR TREATMENT OF TUBERCULOSIS
CN105829891B (zh) * 2013-12-16 2018-04-06 国家血清研究所 用于改进的体内或体外细胞介导的结核病免疫诊断的诊断试剂
SG11201605595YA (en) * 2014-01-09 2016-08-30 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
WO2017205225A2 (en) * 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
CA3098015A1 (en) * 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
KR102577332B1 (ko) * 2021-12-29 2023-09-11 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
CN117777259A (zh) * 2024-02-23 2024-03-29 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1051234C (zh) * 1994-04-15 2000-04-12 焦安国 一种治疗结核病的药物
PT832093E (pt) 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expressão de lipoproteínas
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
WO2001004151A2 (en) 1999-07-13 2001-01-18 Statens Serum Institut TUBERCULOSIS VACCINE AND DIAGNOSTICS BASED ON THE MYCOBACTERIUM TUBERCULOSIS esat-6 GENE FAMILY
EP1278769A2 (en) 2000-04-19 2003-01-29 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
JP3840596B2 (ja) * 2001-01-08 2006-11-01 アイシス・イノベーション・リミテッド ミコバクテリア感染のための治療の効力を決定するためのアッセイ法
EP1350839B1 (en) 2002-04-05 2010-06-02 Institut Pasteur Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of M. bovis BCG and M. microti
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
WO2006009838A2 (en) * 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
NZ581306A (en) * 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EP1833507B1 (en) * 2005-01-05 2011-03-16 Isis Innovation Limited Compositions for immunizing against mycobacterium
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
KR101035053B1 (ko) * 2005-06-23 2011-05-19 스태튼스 세룸 인스티튜트 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
DK2040745T3 (da) * 2006-06-28 2013-03-18 Statens Seruminstitut Udvidelse af T-celle repertoiret til at omfatter subdominante epitoper ved vacci-nation med antigener leveret som proteinfragmenter eller peptidblandinger
LT2315773T (lt) 2008-07-25 2016-11-10 Glaxosmithkline Biologicals S.A. Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui

Also Published As

Publication number Publication date
CA2759583A1 (en) 2010-10-28
HK1166018A1 (zh) 2012-10-19
KR20120014176A (ko) 2012-02-16
AU2010238943A1 (en) 2011-11-03
ES2714383T3 (es) 2019-05-28
US20120039925A1 (en) 2012-02-16
KR20170072366A (ko) 2017-06-26
JP2015199771A (ja) 2015-11-12
BRPI1006452A2 (pt) 2016-12-27
AU2010238943B9 (en) 2015-10-15
TR201903223T4 (tr) 2019-03-21
JP5839361B2 (ja) 2016-01-06
MX370744B (es) 2019-12-20
CN102413837B (zh) 2015-11-25
CA2759583C (en) 2020-06-16
US10519202B2 (en) 2019-12-31
EP2421557A1 (en) 2012-02-29
AU2010238943B2 (en) 2015-09-17
JP6215260B2 (ja) 2017-10-18
WO2010121618A1 (en) 2010-10-28
US9074001B2 (en) 2015-07-07
HK1204549A1 (en) 2015-11-27
IL215591A (en) 2016-03-31
EP2421557B1 (en) 2018-12-05
DK2421557T3 (en) 2019-03-25
ZA201108564B (en) 2018-11-28
CN104107425B (zh) 2018-07-17
CN104107425A (zh) 2014-10-22
PL2421557T3 (pl) 2019-07-31
EP2421557A4 (en) 2013-03-13
US20150093407A1 (en) 2015-04-02
IL215591A0 (en) 2011-12-29
CN102413837A (zh) 2012-04-11
AU2010238943A9 (en) 2015-10-15
JP2012524733A (ja) 2012-10-18

Similar Documents

Publication Publication Date Title
MX2011011186A (es) Una vacuna antituberculosis tb para evitar la reactivacion.
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
ME01156B (me) Postupci i kompozicije za imunizaciju svinja protiv svinjskog cirkovirusa
MX2011012347A (es) Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.
JP2014534202A5 (es)
GB201206559D0 (en) Polypeptide
EA201001212A1 (ru) Лечение микробных инфекций
WO2010019262A3 (en) Polyvalent vaccine
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
NZ702839A (en) Vaccine and methods to reduce campylobacter infection
GB2458057A (en) Francisella strain for live vaccine
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
EP2597151A4 (en) RECOMBINANT MICROORGANISMS, METHODS FOR THE PREPARATION OF VACCINE STRAINS, ANTIGENS, VECTORIZED VACCINE COMPOSITIONS, USES THEREOF, ANTIBODIES, DIAGNOSTIC KIT AND METHODS OF TREATMENT AND / OR PROPHYLAXIS
WO2012174455A3 (en) Group a streptococcus multivalent vaccine
MX2018012270A (es) Novedosas formulaciones de vacuna neumococica.
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
WO2009077744A3 (en) Vaccines for brucellosis
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
MX348934B (es) Secuencias de aminoacidos para el control de patogenos.
GB2515222A (en) Use of flagellin as a vaccine

Legal Events

Date Code Title Description
FG Grant or registration